Craver Brianna M, El Alaoui Kenza, Scherber Robyn M, Fleischman Angela G
Department of Biological Chemistry, University of California Irvine, Irvine, CA 92697, USA.
Department of Internal Medicine, Université Libre de Bruxelles, 1050 Brussels, Belgium.
Cancers (Basel). 2018 Apr 3;10(4):104. doi: 10.3390/cancers10040104.
Hematopoietic stem cells (HSCs) maintain an organism's immune system for a lifetime, and derangements in HSC proliferation and differentiation result in hematologic malignancies. Chronic inflammation plays a contributory if not causal role in HSC dysfunction. Inflammation induces HSC exhaustion, which promotes the emergence of mutant clones that may be resistant to an inflammatory microenvironment; this likely promotes the onset of a myeloid hematologic malignancy. Inflammatory cytokines are characteristically high in patients with myeloid malignancies and are linked to disease initiation, symptom burden, disease progression, and worsened prognostic survival. This review will cover our current understanding of the role of inflammation in the initiation, progression, and complications of myeloid hematologic malignancies, drawing from clinical studies as well as murine models. We will also highlight inflammation as a therapeutic target in hematologic malignancies.
造血干细胞（HSCs）终生维持机体的免疫系统，造血干细胞增殖和分化的紊乱会导致血液系统恶性肿瘤。慢性炎症即使不是导致造血干细胞功能障碍的原因，也起着一定的促成作用。炎症会导致造血干细胞耗竭，从而促进可能对炎症微环境具有抗性的突变克隆的出现；这可能会促进髓系血液系统恶性肿瘤的发生。髓系恶性肿瘤患者体内的炎性细胞因子通常含量较高，并且与疾病的起始、症状负担、疾病进展以及预后生存恶化有关。本综述将借鉴临床研究以及小鼠模型，阐述我们目前对炎症在髓系血液系统恶性肿瘤的起始、进展和并发症中所起作用的理解。我们还将强调炎症作为血液系统恶性肿瘤治疗靶点的重要性。
